Wedbush Downgrades Chinook Therapeutics to Neutral
| KDNYDelisted Stock | USD 39.25 0.20 0.51% |
Slightly above 53% of Chinook Therapeutics' investor base is interested to short. The analysis of current outlook of investing in Chinook Therapeutics suggests that many traders are impartial regarding Chinook Therapeutics' prospects. Chinook Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Chinook Therapeutics' earnings reports, geopolitical events, and overall market trends.
Chinook |
Chinook Therapeutics was downgraded by equities research analysts at Wedbush from an outperform rating to a neutral rating in a report issued on Tuesday, MarketBeat reports. They currently have a 42.00 price objective on the stock. Wedbushs price objective suggests a potential upside of 3.99 percent from the stocks previous close.
Read at thelincolnianonline.com
 |
Chinook Therapeutics Fundamental Analysis
We analyze Chinook Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Chinook Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Chinook Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Earnings Per Share
Earnings Per Share Comparative Analysis
Chinook Therapeutics is currently under evaluation in earnings per share category among its peers. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Chinook Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Chinook Therapeutics stock to make a market-neutral strategy. Peer analysis of Chinook Therapeutics could also be used in its relative valuation, which is a method of valuing Chinook Therapeutics by comparing valuation metrics with similar companies.
Peers
Chinook Therapeutics Related Equities
| PLRX | Pliant Therapeutics | 2.00 | ||||
| DAWN | Day One | 1.53 | ||||
| VTYX | Ventyx Biosciences | 1.13 | ||||
| TVTX | Travere Therapeutics | 0.59 | ||||
| PCVX | Vaxcyte | 0.38 | ||||
| NUVL | Nuvalent | 0.08 | ||||
| ASND | Ascendis Pharma | 0.18 | ||||
| KALV | Kalvista Pharmaceuticals | 0.30 | ||||
| SWTX | SpringWorks Therapeutics | 0.60 | ||||
| RNA | Avidity Biosciences | 0.69 | ||||
| CRNX | Crinetics Pharmaceuticals | 0.81 | ||||
| ACLX | Arcellx | 1.12 | ||||
| KURA | Kura Oncology | 1.16 | ||||
| RVMD | Revolution Medicines | 1.25 | ||||
| VRDN | Viridian Therapeutics | 1.46 | ||||
| GPCR | Structure Therapeutics | 1.78 |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Chinook Stock
If you are still planning to invest in Chinook Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Chinook Therapeutics' history and understand the potential risks before investing.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |